ReviewMedComm2025
Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets.
Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Macrophage programming in systemic sclerosis: Niches, networks, and translational horizons.Seminars in immunopathology · 2026Review
- TGM2-mediated serotonylation of GPX4 confers ferroptosis resistance to promote gastric tumorigenesis.Cell discovery · 2026Article
- A hypothesis and evidence map for neuroimmune regulation of DOCK-family cytoskeletal programs in solid tumors.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally considered to function solely as signaling molecules within the central nervous system (CNS), neurotransmitters are now recognized as key regulators of systemic homeostasis. They modulate interactions among the nervous, immune, and metabolic systems and influence the development of various diseases. This review systematically summarizes the fundamental properties of major neurotransmitters, including their biosynthesis, receptor subtypes, and key signaling pathways, and analyzes their context-dependent roles in cancer, neurodegenerative diseases (NDDs), and inflammatory disorders. A primary focus is the three-dimensional regulatory principle that determines their effects, namely: the receptor type they bind to, cellular microenvironment, and stage of the disease. These factors explain the bidirectional effects of neurotransmitters in disease. This review also evaluates current therapeutic approaches targeting neurotransmitter pathways, ranging from receptor-specific drugs to emerging combination therapies, and discusses challenges in clinical translation, such as off-target effects of nonspecific drugs and variable efficacy across disease types. By linking the fundamental mechanisms of neurotransmitter function to clinical challenges, this review provides a comprehensive framework for exploiting the neurotransmitter-immune axis to develop precise therapeutic strategies aimed at improving outcomes in cancer, NDDs, and inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.